Literature DB >> 23439642

Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin.

A Fekkar1, I Meyer, J Y Brossas, E Dannaoui, M Palous, M Uzunov, S Nguyen, V Leblond, D Mazier, A Datry.   

Abstract

Echinocandin drugs are widely used for the treatment of candidemia. Resistance is considered rare, and only a few cases of breakthrough candidiasis in patients receiving echinocandin have been reported worldwide. We report here for the first time a Candida kefyr isolate that acquired echinocandin resistance very rapidly after the initiation of caspofungin treatment for candidemia. We characterized the FKS gene mutation responsible for the resistance via the comparison of isolates sampled before and during treatment.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23439642      PMCID： PMC3632960          DOI： 10.1128/AAC.02037-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review.

Authors:  Hsin-Yun Sun; Nina Singh
Journal:  Int J Antimicrob Agents       Date:  2009-12-29       Impact factor: 5.283

2.  Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.

Authors:  Santosh Katiyar; Michael Pfaller; Thomas Edlind
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 3.  Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

Authors:  M A Pfaller; D J Diekema; D Andes; M C Arendrup; S D Brown; S R Lockhart; M Motyl; D S Perlin
Journal:  Drug Resist Updat       Date:  2011-02-24       Impact factor: 18.500

Review 4.  Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

Authors:  V Krcmery; A J Barnes
Journal:  J Hosp Infect       Date:  2002-04       Impact factor: 3.926

5.  In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

6.  Acquired resistance to echinocandins in Candida albicans: case report and review.

Authors:  Marie-Thérèse Baixench; Naji Aoun; Marie Desnos-Ollivier; Dea Garcia-Hermoso; Stéphane Bretagne; Sandrine Ramires; Christophe Piketty; Eric Dannaoui
Journal:  J Antimicrob Chemother       Date:  2007-04-27       Impact factor: 5.790

7.  Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.

Authors:  Michel Laverdière; Richard G Lalonde; Jean-Guy Baril; Donald C Sheppard; Steven Park; David S Perlin
Journal:  J Antimicrob Chemother       Date:  2006-02-07       Impact factor: 5.790

8.  Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.

Authors:  Guillermo Garcia-Effron; Samuel Lee; Steven Park; John D Cleary; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

9.  FKS1 mutations responsible for selective resistance of Saccharomyces cerevisiae to the novel 1,3-beta-glucan synthase inhibitor arborcandin C.

Authors:  Takao Ohyama; Shunichi Miyakoshi; Fujio Isono
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae.

Authors:  Santosh K Katiyar; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191
View more
  27 in total

Review 1.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

2.  Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.

Authors:  Rasmus Hare Jensen; Ulrik Stenz Justesen; Annika Rewes; David S Perlin; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

Review 3.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 4.  Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?

Authors:  Danièle Maubon; Cécile Garnaud; Thierry Calandra; Dominique Sanglard; Muriel Cornet
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

Review 5.  Echinocandin Resistance in Candida Species: a Review of Recent Developments.

Authors:  Nathan P Wiederhold
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

6.  Target enzyme mutations confer differential echinocandin susceptibilities in Candida kefyr.

Authors:  Janet F Staab; Dionysios Neofytos; Peter Rhee; Cristina Jiménez-Ortigosa; Sean X Zhang; David S Perlin; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

7.  Update on Antifungal Drug Resistance.

Authors:  David S Perlin; Erika Shor; Yanan Zhao
Journal:  Curr Clin Microbiol Rep       Date:  2015-06-01

8.  Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?

Authors:  A Fekkar; E Dannaoui; I Meyer; S Imbert; J Y Brossas; M Uzunov; G Mellon; S Nguyen; E Guiller; E Caumes; V Leblond; D Mazier; M H Fievet; A Datry
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-09       Impact factor: 3.267

9.  Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.

Authors:  A Forastiero; V Garcia-Gil; O Rivero-Menendez; R Garcia-Rubio; M C Monteiro; A Alastruey-Izquierdo; R Jordan; I Agorio; E Mellado
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

10.  Using Aspergillus nidulans to identify antifungal drug resistance mutations.

Authors:  Xiaoxiao He; Shengnan Li; Susan G W Kaminskyj
Journal:  Eukaryot Cell       Date:  2013-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.